



**Notice Regarding Execution of a Basic Agreement with TOHO HOLDINGS CO., LTD.
Concerning Domestic Distribution of the Stem Cell Product “Stemchymal®”**

—Toward Establishing a Nationwide Stable Supply System Following Approval—

September 29, 2026

REPROCELL Inc. (the “Company”) hereby announces that it has entered into a basic agreement dated September 17, 2026, with TOHO HOLDINGS CO., LTD. (“TOHO HOLDINGS”) toward a partnership concerning the domestic distribution and related activities of the regenerative medical product “Stemchymal®” (“Stemchymal”), for which the Company has submitted an application for manufacturing and marketing approval in Japan.

On June 24, 2026, the Company submitted an application for manufacturing and marketing approval in Japan for Stemchymal, with the indication of suppressing the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6).

Under the basic agreement, the Company and TOHO HOLDINGS will discuss and consider the establishment of a supply system for medical institutions nationwide utilizing the pharmaceutical distribution network of the TOHO HOLDINGS Group, as well as a distribution system tailored to the characteristics of regenerative medical products, with the aim of enabling a smooth market launch and stable supply of Stemchymal following manufacturing and marketing approval.

In parallel with its efforts to obtain manufacturing and marketing approval for Stemchymal, the Company is working to establish a system for the stable supply of the product to medical institutions nationwide following approval and will make every effort to deliver a new treatment option to patients with spinocerebellar ataxia as soon as possible.

The impact of this matter on the Company’s financial performance for the current fiscal year is expected to be minimal at this time; however, should any matters requiring disclosure arise in the future, the Company will promptly disclose them.